Outlook Therapeutics
OTLK
82 hedge funds and large institutions have $29.7M invested in Outlook Therapeutics in 2023 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 34 increasing their positions, 8 reducing their positions, and 7 closing their positions.
325% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 8
100% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 7
9% more funds holding
Funds holding: 75 → 82 (+7)
0% more capital invested
Capital invested by funds: $29.6M → $29.7M (+$125K)
0.07% less ownership
Funds ownership: 0.61% → 0.53% (-0.07%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$1.14M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$532K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$389K |
| 4 |
Millennium Management
New York
|
+$382K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$287K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Altium Capital Management
New York
|
-$3.59M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$201K |
| 3 |
Goldman Sachs
New York
|
-$130K |
| 4 |
VF
Vista Finance
Clayton,
Missouri
|
-$67.1K |
| 5 |
Two Sigma Advisers
New York
|
-$53.7K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PVH
76
Psagot Value Holdings
Tel Aviv,
Israel
| $3K | +$3.15K | +141 | New |
|
|
LFG
77
Larson Financial Group
St Louis,
Missouri
| $2.18K | – | – | – |
|
|
HI
78
Harbour Investments
Madison,
Wisconsin
| $1.42K | – | – | – |
|
|
PWMG
79
Prestige Wealth Management Group
Flemington,
New Jersey
| $1.36K | – | – | – |
|
|
NC
80
NewSquare Capital
Newtown Square,
Pennsylvania
| $218 | – | – | – |
|
81
Commonwealth Equity Services
Waltham,
Massachusetts
| $28 | +$11.2K | +500 | +61% |
|
|
ACM
82
Altium Capital Management
New York
| – | -$3.59M | -166,370 | Closed |
|
|
83
Two Sigma Advisers
New York
| – | -$53.7K | -2,485 | Closed |
|
|
MGP
84
Metis Global Partners
San Diego,
California
| – | -$52.2K | -2,414 | Closed |
|
|
VF
85
Virtu Financial
New York
| – | -$40K | -1,872 | Closed |
|
86
Jane Street
New York
| – | -$19.2K | -889 | Closed |
|
87
Citigroup
New York
| – | -$862 | -40 | Closed |
|
88
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$216 | -10 | Closed |
|
|
CS
89
Credit Suisse
Zurich,
Switzerland
| – | -$5 | – | – |
|
OTLK Hedge Fund Activity: Q1 2023 in Review
82 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Outlook Therapeutics (OTLK) for Q1 2023, worth a combined $29.7M — up 0.42% from $29.6M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new OTLK positions and 7 closed out — a net gain of 7 holders — while 34 added to existing stakes and 8 trimmed.
The largest buyer was BlackRock, adding an estimated $1.14M. The largest seller was Altium Capital Management, exiting entirely with an estimated $3.59M sold.
- 82 institutional investors held Outlook Therapeutics (OTLK) as of Q1 2023, up from 75 in Q4 2022.
- Funds reported $29.7M of Outlook Therapeutics stock for Q1 2023, up 0.42% quarter-over-quarter.
- 14 funds opened new Outlook Therapeutics positions in Q1 2023 and 7 closed out, a net change of +7 holders.
- The largest Outlook Therapeutics buyer in Q1 2023 was BlackRock, an estimated $1.14M added.
- The largest Outlook Therapeutics seller in Q1 2023 was Altium Capital Management, an estimated $3.59M sold.
Based on aggregated 13F filings for Q1 2023.